AXSM
Axsome Therapeutics Inc
NASDAQ: AXSM · HEALTHCARE · BIOTECHNOLOGY
$143.51
+0.92% today
Updated 2026-10-28
Market cap
$8.47B
P/E ratio
—
P/S ratio
10.91x
EPS (TTM)
$-3.74
Dividend yield
—
52W range
$124 – $260
Volume
0.8M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A3.5
Quality
D2.0
Profitability
F6.7
Valuation
B5/9
Piotroski F-Score
Moderate
-2.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$251.00
+74.90%
12-Month target
—
—
Intrinsic (DCF)
$521.33
Margin of safety
+64.28%
3 Strong Buy18 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 45.50% QoQ
+ 64.28% below intrinsic value
Risks
- Altman Z -2.12 — distress zone
- Thin margins at -24.70%
- Negative free cash flow $-33.07M
- Debt/equity 2.63x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $50.04M | $270.60M | $385.69M | $638.50M | $776.57M | $1.4B |
| Net income | $-187.13M | $-239.24M | $-287.22M | $-183.17M | $-51.31M | — |
| EPS | — | — | — | — | $-3.74 | $0.50 |
| Free cash flow | $-117.21M | $-145.66M | $-128.68M | $-93.89M | $-33.07M | — |
| Profit margin | -373.99% | -88.41% | -74.47% | -28.69% | -24.70% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-03 | JACOBSON, MARK L. | Sale | 10,000 | — |
| 2026-09-03 | JACOBSON, MARK L. | Sale | 10,000 | $208.65 |
| 2026-08-06 | TABUTEAU, HERRIOT | Sale | 4,660 | — |
Peer comparison
Smart narrative
Axsome Therapeutics Inc trades at $143.51. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -2.12, it sits in the distress. TTM revenue stands at $776.57M. with profit margins at -24.70%. Our DCF model estimates intrinsic value at $521.33.
Frequently asked questions
What is Axsome Therapeutics Inc's stock price?
Axsome Therapeutics Inc (AXSM) trades at $143.51, on a P/S of 10.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Axsome Therapeutics Inc overvalued?
Axsome Therapeutics Inc carries a Smart Value Score of 30/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $521.33 versus the $143.51 price, a 64.3% margin of safety on a cash flow basis.
What is the price target of Axsome Therapeutics Inc (AXSM)?
The 12-month analyst consensus target is $251.00, about 74.9% above the current $143.51. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of AXSM by 2030?
Our research-backed model puts the 2030 base case at $626.12, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Axsome Therapeutics Inc (AXSM)?
Our DCF model estimates intrinsic value at $521.33, a +64.3% margin of safety versus today's $143.51. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Axsome Therapeutics Inc's revenue?
Axsome Therapeutics Inc's trailing twelve-month revenue is $776.57M, and our model projects it reaching about $5.12B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Axsome Therapeutics Inc's Altman Z-Score is -2.12, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.91x
ROE-344.96%
Beta0.85
50D MA$199.00
200D MA$200.53
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.8M
Performance
1 week-9.55%
1 month-10.77%
3 months+5.55%
YTD+19.36%
1 year+111.60%
3 years—
5 years—